Transient Ischemic Attack clinical trials at UC Health
2 in progress, 1 open to new patients

• Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

  open to eligible people ages 18 years and up

  The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below: 1. Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out. 2. In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between cardioembolic and large artery atherosclerotic. 3. In cases of cardioembolic ischemic stroke, further differentiation of cardioembolic ischemic strokes into those caused by atrial fibrillation (AF) and those not caused by AF. 4. Differentiate "transient ischemic attacks" (TIAs) from acute ischemic strokes. 5. Differentiate TIAs from non-ischemic "transient neurological events" (TNE) with similar symptoms.

  at UCSF

• Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

  Sorry, in progress, not accepting new patients

  The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.

  at UCLA

Last updated: March 25, 2019